GlassScriptPhysician profile
Lisa K Weldon
NPI 1538470851
$5,283.10
in general payments reported to CMS, 2019-2025
42 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $586 · 2022: $1,220 · 2023: $707 · 2024: $1,416 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,430 · Education: $46.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,430.34 |
| Education | $46.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $538.71 | 2021-2025 | Kisunla, Jardiance, Lyumjev |
| Ucb, INC. | $486.43 | 2024-2025 | Briviact, Rystiggo, Fintepla |
| Abbott Laboratories | $427.98 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $310.86 | 2021-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $306.94 | 2021-2024 | Minimed 780g, Mycarelink |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.10 | 2021-2024 | Jardiance |
| Tandem Diabetes Care, INC. | $259.90 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $254.04 | 2021-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $242.96 | 2022-2024 | |
| Zealand Pharma US, INC. | $156.07 | 2021-2022 | |
| Insulet Corporation | $148.60 | 2021-2024 | Omnipod |
| Jazz Pharmaceuticals INC. | $148.02 | 2024-2025 | |
| Neurelis, INC. | $128.56 | 2024-2025 | Valtoco |
| Csl Behring | $121.83 | 2025 | Hizentra |
| Pfizer INC. | $120.43 | 2024-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $117.99 | 2024-2025 | Dysport |
| Argenx US, INC. | $97.95 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $97.17 | 2024-2025 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $84.50 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $79.45 | 2021-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $75.03 | 2021-2025 | Wainua |
| Catalyst Pharmaceuticals, INC. | $71.91 | 2024-2025 | |
| Grifols USA, LLC | $60.56 | 2024-2025 | Gamunex-C, Xembify |
| Alnylam Pharmaceuticals INC. | $57.96 | 2024 | Amvuttra |
| Teva Pharmaceuticals USA, INC. | $51.10 | 2025 | Austedo Xr |
| Kyowa Kirin, INC. | $42.92 | 2024 | Nourianz |
| Amarin Pharma, INC. | $40.69 | 2021-2022 | |
| Eisai INC. | $38.70 | 2024-2025 | |
| Mannkind Corporation | $37.98 | 2024 | |
| Genentech USA, INC. | $37.85 | 2022-2024 | Ocrevus Zunovo |
| Amgen INC. | $37.84 | 2021-2022 | |
| Coloplast Corp | $34.32 | 2023 | Speedicath |
| Merz Pharmaceuticals, LLC | $34.28 | 2025 | Xeomin, Ampyra, Inbrija |
| Abbvie INC. | $34.22 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $32.67 | 2024 | Purified Cortrophin Gel |
| Mdd US Operations, LLC | $30.70 | 2025 | Gocovri |
| Blue Earth Diagnostics | $28.36 | 2021 | |
| Lundbeck LLC | $28.13 | 2025 | Vyepti |
| Sk Life Science, INC. | $27.96 | 2025 | |
| Bard Access Systems, INC. | $26.43 | 2021 | |
| Lifescan, INC. | $18.92 | 2021 | |
| Harmony Biosciences LLC | $15.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Weldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.